Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-12,800
Closed -$2.25M 410
2025
Q4
$2.25M Buy
+12,800
New +$2.09M 0.05% 290
2024
Q4
Sell
-1,800
Closed -$349K 827
2024
Q3
$349K Sell
1,800
-8,600
-83% -$1.8M 0.01% 736
2024
Q2
$2.41M Buy
+10,400
New +$2.26M 0.05% 330
2023
Q4
Sell
-1,600
Closed -$411K 938
2023
Q3
$411K Buy
+1,600
New +$428K ﹤0.01% 873
2023
Q1
Sell
-4,600
Closed -$1.27M 924
2022
Q4
$1.27M Sell
4,600
-1,700
-27% -$480K 0.03% 361
2022
Q3
$1.68M Buy
+6,300
New +$1.34M 0.03% 368
2022
Q2
Sell
-2,200
Closed -$463K 895
2022
Q1
$463K Buy
+2,200
New +$478K 0.02% 563

Other funds holding BIIB

Maven Securities's BIIB Position: Q1 2026 in Review

Maven Securities sold out of Biogen (BIIB) in Q1 2026, closing a stake of 13,069 shares — an estimated $2.3M sold.

Maven Securities first reported a position in BIIB in Q4 2020 and held it in 6 quarters. The position peaked at $2.3M in Q4 2025. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Maven Securities reported no remaining Biogen position as of Q1 2026 after selling out during the quarter.
  • Maven Securities sold 13,069 Biogen shares in Q1 2026, an estimated $2.3M.
  • Maven Securities first reported a position in Biogen in Q4 2020 and held it in 6 quarters.
  • Maven Securities's Biogen position peaked at $2.3M in Q4 2025.
  • 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Maven Securities's 13F filing for Q1 2026, filed 15 May 2026.